Search

Your search keyword '"Sokos, George G."' showing total 41 results
Start Over Author "Sokos, George G."
41 results on '"Sokos, George G."'

1. Effective medications can work only in patients who take them: implications for post acute heart failure care

Author

Cotter, Gad, primary, Davison, Beth A., additional, Adams, Kirkwood F., additional, Ambrosy, Andrew P., additional, Atabaeva, Lina, additional, Beavers, Craig J, additional, Bhatt, Ankeet S., additional, Givertz, Michael M., additional, Grodin, Justin L., additional, Lala, Anuradha, additional, Novosadov, Mikhail, additional, Sokos, George G., additional, Takagi, Koji, additional, Teerlink, John R., additional, and Bhatt, Deepak L., additional

Published
2023
Full Text
View/download PDF

3. Effective medications can work only in patients who take them: Implications for post‐acute heart failure care.

Author

Cotter, Gad, Davison, Beth A., Adams, Kirkwood F., Ambrosy, Andrew P., Atabaeva, Lina, Beavers, Craig J., Bhatt, Ankeet S., Givertz, Michael M., Grodin, Justin L., Lala, Anuradha, Novosadov, Mikhail, Sokos, George G., Takagi, Koji, Teerlink, John R., and Bhatt, Deepak L.

Subjects
HEART failure, PATIENTS' attitudes, DRUGS, MEDICAL personnel, PATIENT compliance, QUALITY of life, CLINICAL trials monitoring
Abstract

Acute heart failure (AHF) is a common cause of hospitalization, particularly among older individuals, and has high mortality and readmission rates. Adherence to guideline-directed medical therapy (GDMT) is crucial for improving outcomes in heart failure (HF) patients, as non-adherence can lead to exacerbations and adverse outcomes. However, studies have shown that medication non-adherence rates among HF patients can be as high as 70%. Various factors contribute to non-adherence, including patient circumstances, treatment-related factors, and healthcare system and payer factors. Adherence interventions, such as patient education, medication regimen management, and reminders, have been shown to improve medication adherence and reduce mortality and hospital readmissions in HF patients. Improving adherence to GDMT is essential for improving AHF outcomes, and further research is needed to identify effective approaches to enhance medication adherence. [Extracted from the article]

Published
2024
Full Text
View/download PDF

4. Evaluating Guideline Directed Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction Post-coronary Artery Bypass Grafting.

Author

Kabulski, Galen M., Boughner, Troy, Szymanski, Thomas W., Sokos, George G., and Kido, Kazuhiko

Subjects
RENIN, VENTRICULAR ejection fraction, CORONARY artery bypass, ANGIOTENSINS, PREOPERATIVE period, SURGICAL complications, RETROSPECTIVE studies, RENIN-angiotensin system, MEDICAL protocols, TREATMENT effectiveness, ADRENERGIC beta blockers, PRE-tests & post-tests, MINERALOCORTICOIDS, DRUG prescribing, DESCRIPTIVE statistics, POSTOPERATIVE period, PHYSICIAN practice patterns, HEART failure, CHEMICAL inhibitors, EVALUATION
Abstract

Background: Limited evidence regarding the use of guideline directed medical therapy (GDMT) in patients with heart failure with reduced ejection fraction (HFrEF) undergoing coronary artery bypass grafting (CABG) is available. Objective: The purpose of this study was to characterize prescription of HFrEF GDMT use before and after CABG. Methods: A retrospective analysis of adult patients with an ejection fraction ≤40% undergoing CABG was performed. The primary objective was to evaluate patients receiving HFrEF GDMT, defined as a heart failure beta-blocker (HFBB) and a renin-angiotensin inhibitor preoperatively and postoperatively. Secondary outcomes included dosing, percent of patients on each individual therapy, mineralocorticoid receptor antagonist (MRA) use, and the combination thereof. The follow up period was 1 year. Results: Thirty-eight patients met criteria for inclusion. Prior to CABG, 52.6% of patients were receiving HFrEF GDMT. The prescribing rate of HFrEF GDMT was not significantly higher at any point within 1 year postoperatively (P =.299). The rate of renin-angiotensin inhibitors, HFBB, and aldosterone antagonists use significantly increased from 13.2% preoperatively to 36.8% at 1 year after CABG (P =.022). Doses of individual therapies were not significantly different across all time points preoperatively and postoperatively. Conclusion: HFrEF GDMT use and doses of individual therapies after CABG were not maximized. Collaborative efforts between cardiac surgeons, heart failure cardiologists, and pharmacists could be used to optimize HFrEF GDMT use and dose titration. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

6. HEMATOLOGICAL ABNORMALITIES IN CARDIOVASCULAR AND CARDIO-ONCOLOGY PATIENTS ARE ASSOCIATED WITH WORSE COVID-19 OUTCOMES

Author

Visaria, Aayush, primary, Hong, Stephanie, additional, Makwana, Priyal, additional, Wen, Sijin, additional, Chapman, Scott, additional, Khodaverdi, Maryam, additional, Singh, Jasvinder, additional, Ogungbe, Oluwabunmi, additional, Neumann, Jacob, additional, Mazimba, Sula, additional, Sokos, George G., additional, and Patel, Brijesh D., additional

Published
2022
Full Text
View/download PDF

20. Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan

Author

Sokos,George G and Raina,Amresh

Subjects
Vascular Health and Risk Management
Abstract

George G Sokos, 1 Amresh Raina 2 1Department of Medicine, Division of Cardiology, West Virginia School of Medicine, Morgantown, WV, USA; 2Pulmonary Hypertension Program, Section of Heart Failure/Transplant/MCS & Pulmonary Hypertension, Allegheny General Hospital, AGH McGinnis Cardiovascular Institute, Pittsburgh, PA, USACorrespondence: George G SokosAdvanced Heart Failure, WVU Heart & Vascular Institute, 1 Medical Center Drive, Box 8003 Morgantown, WV 26506, USATel +1 304 598 4478Fax +1 304 598 4779Email George.Sokos@hsc.wvu.eduAbstract: This review aims to elucidate the optimal dosing of angiotensin receptor-neprilysin inhibitor (ARNI) therapy in the heart failure (HF) treatment paradigm through examination of the trial population characteristics and the mortality benefit observed in the Prospective Comparison of ARNI with angiotensin-converting enzyme inhibitor (ACEI) to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF; NCT01035255) trial. Considerations regarding the initiation and titration of sacubitril/valsartan, a first-in-class ARNI, will also be addressed. The approval of sacubitril/valsartan heralded the first novel pharmacological class in over a decade for the treatment of heart failure with reduced ejection fraction (HFrEF). The PARADIGM-HF trial showed that treatment with valsartan/valsartan reduced the risk of first occurrence of either cardiovascular death or HF-related hospitalization (composite primary endpoint) by 20% compared with enalapril in patients with HFrEF. The incremental benefits of treatment with valsartan/valsartan over enalapril demonstrated in the PARADIGM-HF trial led to strong recommendations for its use over ACEIs or angiotensin receptor blockers to further reduce morbidity and mortality in the 2016and 2017 American College of Cardiology/American Heart Association/Heart Failure Society of America updates to the guidelines for the management of HF. Although the optimal timing for the initiation of valsartan/valsartan has yet to be determined, its early use is likely to have a positive impact on patient outcomes.Keywords: angiotensin receptor-neprilysin inhibitor, cardiovascular death, patient outcomes, treatment recommendations

Published
2020

25. Sexual Function After Left Ventricular Assist Device

Author

Eckman, Peter M., primary, Dhungel, Vinayak, additional, Mandras, Stacy, additional, Brisco, Meredith A., additional, Emani, Sitaramesh, additional, Duval, Sue, additional, Lindenfeld, JoAnn, additional, Sulemanjee, Nasir, additional, Sokos, George G., additional, and Feldman, Jamie, additional

Published
2013
Full Text
View/download PDF

37. Abstract 268

Author

Sokos, George G, Lazar, Jessica, Hilliard, Terri, Ozanich, Evelyn, Raina, Amresh, Kanwar, Manreet, Benza, Raymond L, and Murali, Srinivas

Published
2012

39. MORTALITY AND READMISSION TREND OF HEART FAILURE WITH PRESERVED AND REDUCED EJECTION FRACTION BASED ON HOME-HOSPITAL DISTANCE: AN ANALYSIS OF APPALACHIAN REGIONAL HEARTY FAILURE REGISTRIES.

Author

Sattar, Yasar, Challa, Abhiram, Alruwaili, Waleed, Bianco, Christopher, Caccamo, Marco, Fang, Wei, Haleem, Affan, Kimble, Wesley, Morgan, Emily, Witrick, Brian, Felpel, Kevin D., and Sokos, George G.

Subjects
*VENTRICULAR ejection fraction, *HEART failure, *PATIENT readmissions, *MORTALITY
Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results